Biomea Fusion announced it will present Phase 1 clinical trial results for BMF-650, an investigational oral GLP-1 receptor agonist for diabetes and obesity, at ObesityWeek 2026 in November. The results highlight BMF-650’s potential as a next-generation treatment targeting metabolic disorders affecting millions globally. The presentation will provide insights into the drug’s safety and efficacy, supporting Biomea’s mission to develop transformative therapies for diabetes and obesity. The poster will be available on Biomea’s website after the conference.
Biomea Fusion's investigational oral GLP-1 receptor agonist BMF-650 is the subject, with Pluang data providing context for health-sector stocks. As of Nov 10, 2026 18:42 WIB, out of 150 priced health-sector US stocks on Pluang, 85 rose and 56 fell. Notable movers include Revvity Inc (RVTY) at USD 163.18 with a 1-day change of +1.53% and a typical hold time of 14 days, LifeStance Health Group Inc. (LFST) at USD 14.81 with a +1.44% change and 12 days hold, and Enveric Biosciences Inc (ENVB) at USD 1.46 with a +1.39% change and 16 days hold time.
The 2026 Verizon Data Breach Investigations Report links 61% of manufacturing breaches to third parties and 81% to internal data compromise. Manufacturers adopting Microsoft 365 Copilot should carefully manage which engineering and supplier files emp...
Soleo Health has been selected as a specialty pharmacy partner for Pasatru™ (garetosmab-grts), Regeneron's FDA-approved treatment for adults with fibrodysplasia ossificans progressiva (FOP), an ultra-rare genetic disorder. Pasatru™ is the first treat...
PsiThera raised $25 million in financing led by new investors AbbVie Ventures and Lumination Capital, alongside existing backers. The funds will support development of its oral small molecule TNFα inhibitor and advance its oral TL1A inhibitors into l...
Opus Genetics announced its Q3 2026 financial results and significant progress in its gene therapy programs for inherited retinal diseases. Key milestones include completion of dosing in OPGx-BEST1 Cohort 2 with data expected in Q1 2027, full enrollm...
Iveco Group is exhibiting its latest products, including new light and heavy-duty vehicles powered by FPT engines, at Fenatran 2026 in São Paulo, highlighting its strong industrial and commercial presence in Latin America. The event marks the regiona...
